title: Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials.
abstract: OBJECTIVE
  We performed a meta-analysis to explore the effects of adding statins to standard treatment on adult patients of pulmonary hypertension (PH).
  
  
  METHODS
  A systematic search up to December, 2015 of Medline, EMBASE, Cochrane Database of Systematic reviews and Cochrane Central Register of Controlled Trials was performed to identify randomized controlled trials with PH patients treated with statins.
  
  
  RESULTS
  Five studies involving 425 patients were included into this meta-analysis. The results of our analysis showed that the statins can't significantly increase 6-minute walking distance (6MWD, mean difference [MD] = -0.33 [CI: -18.25 to 17.59]), decrease the BORG dyspnea score (MD = -0.72 [CI: -2.28 to 0.85]), the clinical worsening risk (11% in statins vs. 10.1% in controls, Risk ratio = 1.06 [CI: 0.61, 1.83]), or the systolic pulmonary arterial pressure (SPAP) (MD = -0.72 [CI: -2.28 to 0.85]). Subgroup analysis for PH due to COPD or non-COPD also showed no significance.
  
  
  CONCLUSIONS
  Statins have no additional beneficial effect on standard therapy for PH, but the results from subgroup of PH due to COPD seem intriguing and further study with larger sample size and longer follow-up is suggested.
authors.affiliation: Department of Cardiology, Chengdu Shang Jin Nan Fu Hospital, Chengdu, Sichuan Province, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Cardiology, West China hospital of Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: Moying
authors.initials: M
authors.lastname: Qu
authors.affiliation: Department of Emergency, West China hospital of Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Emergency, West China hospital of Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: Yaxiong
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Emergency, West China hospital of Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Wan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure; D017079:Exercise Tolerance; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000070857:Walk Test; D055815:Young Adult
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D058986:Phosphodiesterase 5 Inhibitors